VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ZYXIZynex, Inc.
$0.06$2M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ZYXI logoZynex, Inc.(ZYXI)Earnings, Financials & Key Ratios

ZYXI•NASDAQ
0.6× P/E·Price updated Apr 28, 2026
SectorHealthcareIndustryMedical DistributionSub-IndustryHome Health Equipment and Supplies
AboutZynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Show more
  • Revenue$192M+4.4%
  • EBITDA$11M-28.2%
  • Net Income$3M-69.2%
  • EPS (Diluted)0.09-66.7%
  • Gross Margin79.5%+0.4%
  • EBITDA Margin5.6%-31.2%
  • Operating Margin3.11%-46.8%
  • Net Margin1.56%-70.5%
  • ROE7.32%-57.7%

ZYXI Key Insights

Zynex, Inc. (ZYXI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 33.4%
  • ✓Good 3Y average ROE of 16.3%
  • ✓Share count reduced 10.6% through buybacks
  • ✓Trading at only 0.0x book value
  • ✓Efficient asset utilization: 1.6x turnover

✗Weaknesses

  • ✗High debt to equity ratio of 2.1x
  • ✗Profits declining 20.6% over 5 years
  • ✗Weak momentum: RS Rating 5 (bottom 5%)
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ZYXI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ZYXI Price & Volume

Zynex, Inc. (ZYXI) stock price & volume — 10-year historical chart

Loading chart...

ZYXI Growth Metrics

Zynex, Inc. (ZYXI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years32.99%
5 Years33.44%
3 Years13.86%
TTM-44.13%

Profit CAGR

10 Years-
5 Years-20.61%
3 Years-44.06%
TTM-1633.13%

EPS CAGR

10 Years-
5 Years-18.48%
3 Years-39.18%
TTM-1741.28%

Return on Capital

10 Years179.4%
5 Years17.26%
3 Years12.38%
Last Year5.36%

ZYXI Peer Comparison

Zynex, Inc. (ZYXI) competitors in Home Health Equipment and Supplies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
STIM logoSTIMNeuronetics, Inc.Direct Competitor85.59M1.23-2.0899.17%-24.48%-139.83%3.44
ENVA logoENVAEnova International, Inc.Direct Competitor5.05B202.5517.4918.58%9.95%24.88%3.41
GMED logoGMEDGlobus Medical, Inc.Direct Competitor10.69B79.2320.2116.65%18.92%13.04%0.03
ABT logoABTAbbott LaboratoriesProduct Competitor153.68B88.3811.574.59%31.88%27.26%0.32
MDT logoMDTMedtronic plcProduct Competitor101.86B79.3421.983.62%13%9.49%0.59
BSX logoBSXBoston Scientific CorporationProduct Competitor67.31B45.2923.3519.87%14.4%12.4%0.51
SYK logoSYKStryker CorporationProduct Competitor117.88B307.8036.6411.16%12.92%15.04%0.66
LIVN logoLIVNLivaNova PLCProduct Competitor4.31B78.50-17.6410.74%7.47%9.13%0.39

Compare ZYXI vs Peers

Zynex, Inc. (ZYXI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs STIM

Most directly comparable listed peer for ZYXI.

Scale Benchmark

vs UNH

Larger-name benchmark to compare ZYXI against a more recognizable public peer.

Peer Set

Compare Top 5

vs STIM, ENVA, GMED, ABT

ZYXI Income Statement

Zynex, Inc. (ZYXI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Sales/Revenue
13.31M23.43M31.92M45.47M80.12M130.3M158.17M184.32M192.35M108.2M
Revenue Growth %
14.36%76.01%36.21%42.47%76.2%62.63%21.39%16.54%4.36%-44.13%
Cost of Goods Sold
3.52M4.82M6.04M8.81M17.42M26.92M32.01M38.37M39.43M30.69M
COGS % of Revenue
26.42%20.57%18.92%19.38%21.74%20.66%20.23%20.81%20.5%-
Gross Profit
9.8M▲ 0%
18.61M▲ 90.0%
25.88M▲ 39.0%
36.66M▲ 41.7%
62.7M▲ 71.1%
103.38M▲ 64.9%
126.16M▲ 22.0%
145.96M▲ 15.7%
152.93M▲ 4.8%
77.51M▲ 0%
Gross Margin %
73.58%79.43%81.08%80.62%78.26%79.34%79.77%79.19%79.5%71.64%
Gross Profit Growth %
46.12%90.01%39.04%41.65%71.05%64.87%22.04%15.69%4.77%-
Operating Expenses
9.16M9.67M15.51M25.59M52.46M81.01M103.22M135.18M146.94M145.42M
OpEx % of Revenue
68.77%41.26%48.59%56.28%65.47%62.17%65.26%73.34%76.39%-
Selling, General & Admin
9.16M9.67M15.51M25.59M52.46M77.46M103.22M135.18M146.94M114.68M
SG&A % of Revenue
68.77%41.26%48.59%56.28%65.47%59.45%65.26%73.34%76.39%-
Research & Development
256K100K200K600K02.6M00012M
R&D % of Revenue
1.92%0.43%0.63%1.32%-2%----
Other Operating Expenses
-204K00880K0949K0000
Operating Income
640K▲ 0%
8.94M▲ 1297.5%
10.37M▲ 15.9%
11.07M▲ 6.7%
10.25M▼ 7.4%
22.37M▲ 118.2%
22.94M▲ 2.6%
10.78M▼ 53.0%
5.99M▼ 44.4%
-67.91M▲ 0%
Operating Margin %
4.81%38.17%32.49%24.34%12.79%17.16%14.5%5.85%3.11%-62.76%
Operating Income Growth %
125.8%1297.5%15.94%6.71%-7.38%118.23%2.56%-53%-44.43%-
EBITDA
1.07M9.23M10.82M11.84M11.82M24.65M26.07M15M10.77M-64.31M
EBITDA Margin %
8.07%39.39%33.89%26.05%14.75%18.92%16.48%8.14%5.6%-59.44%
EBITDA Growth %
152.26%758.6%17.2%9.48%-0.19%108.54%5.73%-42.45%-28.19%-580.71%
D&A (Non-Cash Add-back)
435K286K448K778K1.57M2.29M3.13M4.22M4.78M3.6M
EBIT
640K8.94M10.37M11.07M10.17M22.37M22.64M13.67M6.01M-67.91M
Net Interest Income
-352K-1.45M-154K-5K-19K-95K-440K-1.09M-2.38M-3.04M
Interest Income
0000000000
Interest Expense
352K1.45M154K5K19K95K440K1.09M2.38M3.04M
Other Income/Expense
-556K-1.45M-154K875K-96K-95K-740K1.8M-2.36M-3.04M
Pretax Income
84K▲ 0%
7.49M▲ 8821.4%
10.22M▲ 36.3%
11.94M▲ 16.9%
10.15M▼ 15.0%
22.27M▲ 119.4%
22.2M▼ 0.3%
12.58M▼ 43.3%
3.63M▼ 71.2%
-70.95M▲ 0%
Pretax Margin %
0.63%31.98%32.01%26.26%12.67%17.09%14.03%6.82%1.89%-65.57%
Income Tax
15K129K664K2.45M1.08M5.17M5.15M2.85M633K3.01M
Effective Tax Rate %
17.86%1.72%6.5%20.51%10.63%23.21%23.2%22.63%17.45%-4.24%
Net Income
69K▲ 0%
7.37M▲ 10573.9%
9.55M▲ 29.7%
9.49M▼ 0.6%
9.07M▼ 4.4%
17.1M▲ 88.5%
17.05M▼ 0.3%
9.73M▼ 42.9%
2.99M▼ 69.2%
-73.96M▲ 0%
Net Margin %
0.52%31.43%29.93%20.87%11.33%13.13%10.78%5.28%1.56%-68.35%
Net Income Growth %
102.37%10573.91%29.69%-0.63%-4.4%88.48%-0.32%-42.91%-69.24%-1633.13%
Net Income (Continuing)
69K7.37M9.55M9.49M9.07M17.1M17.05M9.73M2.99M-73.96M
Discontinued Operations
0000000000
Minority Interest
-89K-89K-89K-89K000000
EPS (Diluted)
0.00▲ 0%
0.20▲ 9900.0%
0.26▲ 30.0%
0.25▼ 3.8%
0.24▼ 4.0%
0.40▲ 66.7%
0.44▲ 10.0%
0.27▼ 38.6%
0.09▼ 66.7%
-2.44▲ 0%
EPS Growth %
102.36%-30%-3.85%-4%66.67%10%-38.64%-66.67%-1741.28%
EPS (Basic)
0.000.210.270.270.240.410.440.270.09-
Diluted Shares Outstanding
34.4M36.52M37.45M37.36M38.44M43.12M39.13M36.14M32.3M30.31M
Basic Shares Outstanding
34.4M35.37M35.75M35.68M37.26M42.15M38.47M35.55M31.94M30.31M
Dividend Payout Ratio
---23.83%-0.01%21.19%0.03%0.3%-

ZYXI Balance Sheet

Zynex, Inc. (ZYXI) balance sheet — assets, liabilities & shareholders' equity

MetricDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Total Current Assets
3.42M8.37M14.33M22.57M63.02M82.69M69.56M87.86M75.18M37.02M
Cash & Short-Term Investments
247K5.57M10.13M14.04M39.17M42.61M20.14M44.58M39.63M13.26M
Cash Only
247K5.57M10.13M14.04M39.17M42.61M20.14M44.58M39.63M13.26M
Short-Term Investments
0000000000
Accounts Receivable
3.03M2.19M2.79M5.83M13.84M28.63M35.06M26.84M18.02M6.7M
Days Sales Outstanding
83.0234.0431.9246.8263.0480.280.9153.1534.241.42
Inventory
107K423K837K2.38M8.63M10.76M13.48M13.11M13.92M11.99M
Days Inventory Outstanding
11.132.0450.698.48180.96145.83153.78124.69128.85153.59
Other Current Assets
000315K1.38M689K868K3.33M05.07M
Total Non-Current Assets
669K558K1.86M5.71M11.2M50.59M50.79M49.05M46.9M8.31M
Property, Plant & Equipment
580K188K819K4.87M8.24M18.52M15.29M16.22M14.04M8M
Fixed Asset Turnover
22.95x124.64x38.97x9.34x9.72x7.03x10.35x11.37x13.70x9.42x
Goodwill
0000020.4M20.4M20.4M20.4M0
Intangible Assets
34K00009.97M9.07M8.16M7.25M0
Long-Term Investments
0000000000
Other Non-Current Assets
55K370K314K329K347K974K591K409K5.21M310K
Total Assets
4.09M▲ 0%
8.93M▲ 118.3%
16.18M▲ 81.3%
28.28M▲ 74.7%
74.22M▲ 162.5%
133.27M▲ 79.6%
120.35M▼ 9.7%
136.9M▲ 13.8%
122.08M▼ 10.8%
45.32M▲ 0%
Asset Turnover
3.25x2.62x1.97x1.61x1.08x0.98x1.31x1.35x1.58x1.21x
Asset Growth %
10.69%118.26%81.25%74.72%162.49%79.56%-9.7%13.75%-10.83%-123.24%
Total Current Liabilities
7.75M4.01M6.36M5.2M10.12M22.87M21.09M18.53M16.86M78.85M
Accounts Payable
2.88M2.25M1.55M2.13M4.72M4.74M5.6M8.43M7.09M12.52M
Days Payables Outstanding
298.79170.893.8288.3398.8564.2563.8880.2365.64104.46
Short-Term Debt
2.77M231K01.26M2.13M8.31M7.94M0063.77M
Deferred Revenue (Current)
54K880K-685K0000000
Other Current Liabilities
826K880K3.84M8K02.95M16K000
Current Ratio
0.44x2.08x2.25x4.34x6.23x3.62x3.30x4.74x4.46x0.47x
Quick Ratio
0.43x1.98x2.12x3.88x5.38x3.15x2.66x4.03x3.63x0.32x
Cash Conversion Cycle
-204.66-104.72-11.356.97145.14161.78170.8297.697.4190.55
Total Non-Current Liabilities
148K12K531K3.43M7.25M36.48M32.91M72.24M69.51M7.85M
Long-Term Debt
0000010.61M5.29M57.6M58.57M0
Capital Lease Obligations
136K02.98M3.43M5.2M16.17M13.73M14.64M10.94M37.52M
Deferred Tax Liabilities
00002.05M4.81M3.88M001.94M
Other Non-Current Liabilities
12K00009.7M10M000
Total Liabilities
7.89M4.03M6.89M8.62M17.37M59.35M53.99M90.78M86.37M86.69M
Total Debt
3.02M354K3.66M4.68M7.33M38.06M26.96M76.17M73.82M71.62M
Net Debt
2.78M-5.21M-6.47M-9.36M-31.84M-4.55M6.82M31.59M34.19M58.36M
Debt / Equity
-0.07x0.39x0.24x0.13x0.51x0.41x1.65x2.07x-1.73x
Debt / EBITDA
2.81x0.04x0.34x0.40x0.62x1.54x1.03x5.08x6.85x-1.11x
Net Debt / EBITDA
2.58x-0.56x-0.60x-0.79x-2.69x-0.18x0.26x2.11x3.17x-0.91x
Interest Coverage
1.82x6.17x67.34x2213.20x535.37x235.43x51.45x12.50x2.52x-22.32x
Total Equity
-3.8M▲ 0%
4.9M▲ 228.9%
9.3M▲ 89.7%
19.65M▲ 111.4%
56.85M▲ 189.3%
73.92M▲ 30.0%
66.36M▼ 10.2%
46.13M▼ 30.5%
35.71M▼ 22.6%
-41.37M▲ 0%
Equity Growth %
6.61%228.93%89.68%111.37%189.29%30.02%-10.24%-30.48%-22.59%-371.64%
Book Value per Share
-0.110.130.250.531.481.711.701.281.11-1.36
Total Shareholders' Equity
-3.71M4.99M9.39M19.74M56.85M73.92M66.36M46.13M35.71M-41.37M
Common Stock
31K33K34K34K36K41K39K33K32K30K
Retained Earnings
-9.78M-2.41M4.87M14.36M23.43M017.05M26.78M29.77M-43.57M
Treasury Stock
0-243K-3.67M-3.85M-3.85M-6.51M-33.16M-71.56M-87.19M-92.12M
Accumulated OCI
0000000000
Minority Interest
-89K-89K-89K-89K000000

ZYXI Cash Flow Statement

Zynex, Inc. (ZYXI) cash flow — operating, investing & free cash flow history

MetricDec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24TTM
Cash from Operations
1.7M8.26M9.41M6.3M818K6.95M13.75M17.76M12.72M-20.57M
Operating CF Margin %
12.77%35.25%29.48%13.86%1.02%5.33%8.69%9.63%6.61%-
Operating CF Growth %
398.53%385.88%13.9%-33%-87.02%749.51%97.81%29.17%-28.36%-1504.28%
Net Income
69K7.37M9.55M9.49M9.07M17.1M17.05M9.73M2.99M-73.96M
Depreciation & Amortization
435K286K448K778K1.57M2.29M3.13M4.22M4.78M4.08M
Stock-Based Compensation
200K66K370K820K2.68M1.63M2.34M2.3M2.99M2.1M
Deferred Taxes
285K227K-725K212K-54K-146K-851K-2.3M-934K4.53M
Other Non-Cash Items
200K1.48M370K-695K-236K1.29M1.18M-2.08M-1.05M30.07M
Working Capital Changes
511K-1.16M-607K-4.3M-12.22M-15.21M-9.1M5.89M3.94M12.62M
Change in Receivables
-1.09M843K-606K-3.04M-8M-14.78M-6.43M8.22M8.82M14.93M
Change in Inventory
198K-316K-414K-2.36M-7.32M-3.78M-4.32M-1.45M-2.74M2.53M
Change in Payables
402K-1.22M-515K1.02M3.03M2.89M1.83M269K-2.07M-3.18M
Cash from Investing
-174K-87K-1.08M-160K-985K-16.61M-418K-966K-578K-431K
Capital Expenditures
-226K-87K-1.08M-160K-985K-609K-418K-1.21M-578K-431K
CapEx % of Revenue
1.7%0.37%3.39%0.35%1.23%0.47%0.26%0.65%0.3%0.4%
Acquisitions
00000-16M0000
Investments
----------
Other Investing
-174K00000050K00
Cash from Financing
-1.3M-2.85M-3.76M-2.23M25.3M13.1M-35.8M7.64M-17.09M-3.37M
Debt Issued (Net)
-72K-2.52M-507K-19K-57K15.86M-5.45M46.22M-334K1.87M
Equity Issued (Net)
0-183K-3.26M-171K25.2M-2.51M-26.38M-38.66M-15.63M9K
Dividends Paid
000-2.26M0-1K-3.61M-3K-9K0
Share Repurchases
0-377K-3.43M-171K0-2.67M-26.43M-37.92M-15.63M0
Other Financing
-1.23M-155K0221K154K-252K-352K86K-1.12M-5.25M
Net Change in Cash
239K▲ 0%
5.32M▲ 2125.1%
4.56M▼ 14.2%
3.91M▼ 14.3%
25.13M▲ 542.5%
3.44M▼ 86.3%
-22.47M▼ 753.3%
24.43M▲ 208.8%
-4.95M▼ 120.2%
-24.37M▲ 0%
Free Cash Flow
1.47M▲ 0%
8.17M▲ 454.5%
8.33M▲ 1.9%
6.14M▼ 26.2%
-167K▼ 102.7%
6.34M▲ 3896.4%
13.33M▲ 110.2%
16.55M▲ 24.2%
12.14M▼ 26.6%
-21M▲ 0%
FCF Margin %
11.07%34.88%26.09%13.51%-0.21%4.87%8.43%8.98%6.31%-19.41%
FCF Growth %
332.26%454.48%1.87%-26.22%-102.72%3896.41%110.22%24.17%-26.63%-235.24%
FCF per Share
0.040.220.220.16-0.000.150.340.460.38-0.69
FCF Conversion (FCF/Net Income)
24.64x1.12x0.98x0.66x0.09x0.41x0.81x1.82x4.25x0.28x
Interest Paid
00772K5K894K82K3.62M3.06M3M0
Taxes Paid
0012K2.87M19K3.31M6.29M6.46M2.58M0

ZYXI Key Ratios

Zynex, Inc. (ZYXI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201620172018201920202021202220232024TTM
Return on Equity (ROE)
-1339.09%134.54%65.57%23.72%26.16%24.31%17.3%7.32%-1807.05%
Return on Invested Capital (ROIC)
--616.53%126.44%43.54%35.54%24.14%10.72%6.09%-95.63%
Gross Margin
73.58%79.43%81.08%80.62%78.26%79.34%79.77%79.19%79.5%71.64%
Net Margin
0.52%31.43%29.93%20.87%11.33%13.13%10.78%5.28%1.56%-68.35%
Debt / Equity
-0.07x0.39x0.24x0.13x0.51x0.41x1.65x2.07x-1.73x
Interest Coverage
1.82x6.17x67.34x2213.20x535.37x235.43x51.45x12.50x2.52x-22.32x
FCF Conversion
24.64x1.12x0.98x0.66x0.09x0.41x0.81x1.82x4.25x0.28x
Revenue Growth
14.36%76.01%36.21%42.47%76.2%62.63%21.39%16.54%4.36%-44.13%
Related:ZYXI Dividend History·ZYXI Revenue History·ZYXI Price History·ZYXI P/E History·ZYXI Financial Ratios·ZYXI Institutional Holders

ZYXI SEC Filings & Documents

Zynex, Inc. (ZYXI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Mar 26, 2026·SEC

Material company update

Mar 20, 2026·SEC

Material company update

Feb 19, 2026·SEC

10-K Annual Reports

2
FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 12, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 17, 2025·SEC

FY 2025

Jul 31, 2025·SEC

FY 2025

Apr 29, 2025·SEC

ZYXI Frequently Asked Questions

Zynex, Inc. (ZYXI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Zynex, Inc. (ZYXI) reported $108.2M in revenue for fiscal year 2024. This represents a 871513% increase from $0.0M in 1998.

Zynex, Inc. (ZYXI) grew revenue by 4.4% over the past year. Growth has been modest.

Zynex, Inc. (ZYXI) reported a net loss of $74.0M for fiscal year 2024.

Dividend & Returns

Yes, Zynex, Inc. (ZYXI) pays a dividend with a yield of 0.51%. This makes it attractive for income-focused investors.

Zynex, Inc. (ZYXI) has a return on equity (ROE) of 7.3%. This is below average, suggesting room for improvement.

Zynex, Inc. (ZYXI) had negative free cash flow of $21.0M in fiscal year 2024, likely due to heavy capital investments.

What if you invested $1,000 in ZYXI back in 1998?

Total return calculator · dividends reinvested · 28+ years of data

See returns →

How much would $100/month in ZYXI be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →